Cytek Biosciences Stock Current Valuation
| CTKB Stock | USD 5.42 0.11 1.99% |
Valuation analysis of Cytek Biosciences helps investors to measure Cytek Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 1.9 B, whereas Enterprise Value Over EBITDA is projected to grow to (61.02). Fundamental drivers impacting Cytek Biosciences' valuation include:
Price Book 1.8122 | Enterprise Value 455.8 M | Enterprise Value Ebitda (133.96) | Price Sales 3.5436 | Forward PE 370.3704 |
Undervalued
Today
Please note that Cytek Biosciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cytek Biosciences is based on 3 months time horizon. Increasing Cytek Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cytek Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cytek Stock. However, Cytek Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.42 | Real 5.87 | Target 12.25 | Hype 5.42 | Naive 5.05 |
The real value of Cytek Stock, also known as its intrinsic value, is the underlying worth of Cytek Biosciences Company, which is reflected in its stock price. It is based on Cytek Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cytek Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cytek Biosciences helps investors to forecast how Cytek stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytek Biosciences more accurately as focusing exclusively on Cytek Biosciences' fundamentals will not take into account other important factors: Cytek Biosciences Company Current Valuation Analysis
Cytek Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cytek Biosciences Current Valuation | 455.81 M |
Most of Cytek Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytek Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cytek Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytek Biosciences is extremely important. It helps to project a fair market value of Cytek Stock properly, considering its historical fundamentals such as Current Valuation. Since Cytek Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytek Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytek Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Cytek Current Valuation Historical Pattern
Today, most investors in Cytek Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cytek Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cytek Biosciences current valuation as a starting point in their analysis.
Cytek Biosciences Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cytek Biosciences has a Current Valuation of 455.81 M. This is 96.83% lower than that of the Health Care Equipment & Supplies sector and 96.33% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.26% higher than that of the company.
Cytek Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytek Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics of similar companies.Cytek Biosciences is currently under evaluation in current valuation category among its peers.
Cytek Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cytek Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cytek Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cytek Fundamentals
| Return On Equity | -0.0282 | ||||
| Return On Asset | -0.0306 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 455.81 M | ||||
| Shares Outstanding | 131.27 M | ||||
| Shares Owned By Insiders | 8.74 % | ||||
| Shares Owned By Institutions | 66.40 % | ||||
| Number Of Shares Shorted | 6.58 M | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 3.54 X | ||||
| Revenue | 193.01 M | ||||
| Gross Profit | 100.97 M | ||||
| EBITDA | (17.11 M) | ||||
| Net Income | (12.15 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 33.17 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.99 X | ||||
| Cash Flow From Operations | 5.28 M | ||||
| Short Ratio | 8.61 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 637 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 711.5 M | ||||
| Total Asset | 497.67 M | ||||
| Retained Earnings | (29.18 M) | ||||
| Working Capital | 335.83 M | ||||
| Net Asset | 497.67 M |
About Cytek Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytek Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytek Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytek Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Cytek Stock
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Cytek Biosciences Piotroski F Score and Cytek Biosciences Altman Z Score analysis. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.09) | Revenue Per Share 1.497 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.